HPV Infection
4
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
1
1
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Vaccine
1100%
+ 3 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
LP
Lee's PharmaceuticalChina - Guangzhou
2 programs1
1
Yallaferon®Phase 2/31 trial
Recombinant Human Interferon a-2b GelPhase 21 trial
Active Trials
Design TherapeuticsCARLSBAD, CA
1 program1
9vHPV Vaccine plus BCG Vaccine Mix for percutaneous usePhase 1Vaccine1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Lee's PharmaceuticalYallaferon®
Lee's PharmaceuticalRecombinant Human Interferon a-2b Gel
Barinthus BiotherapeuticsChAdOx1-HPV
Design Therapeutics9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use
Clinical Trials (4)
Total enrollment: 553 patients across 4 trials
Recombinant Human Interferon a-2b Gel for HPV Gynecological Infections
Start: Mar 2011Est. completion: Sep 2012325 patients
Phase 2/3Completed
Yallaferon in Chinese Population
Start: Sep 2015Est. completion: Nov 2016100 patients
Phase 2Unknown
Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions
Start: Mar 2021Est. completion: Jan 2024108 patients
Phase 1/2Completed
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV
Start: Apr 2025Est. completion: Sep 202620 patients
Phase 1Active Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space